The secondary objectives were to correlate Ki-67 labelling index with the known biological behavior and aggressiveness of the different ameloblastoma variants, to evaluate the association between Ki-67 expression and clinicodemographic variables such as age, sex, site, and jaw involvement, and to assess the potential utility of Ki-67 labelling index as a prognostic indicator for biological aggressiveness, recurrence risk, and treatment planning in ameloblastoma. Here, MKI67 is linked to ameloblastoma.